600530.SH
Shanghai Jiaoda Onlly Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 3.45
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 309.5M | 314.1M | 325.2M | 296.3M | 377.2M |
| Cost of Revenue | 215.8M | 221.6M | 227.7M | 229.7M | 230.7M |
| Gross Profit | 93.7M | 92.6M | 97.5M | 66.6M | 146.4M |
| Operating Expenses | |||||
| R&D Expense | 5.7M | 6.4M | 5.2M | 5.9M | 11.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 46.1M | 44.7M | 43.0M | 42.1M | 36.3M |
| Selling & Marketing Expense | 28.7M | 29.2M | 28.8M | 29.9M | 39.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 95.4M | 94.3M | 90.0M | 94.2M | 106.7M |
| Cost and Expenses | 311.3M | 315.8M | 317.7M | 323.9M | 337.5M |
| Operating Income (EBIT) | 14.3M | 14.1M | 40.4M | (25.6M) | (479.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 15.6M | 15.6M | 39.0M | (30.4M) | (481.5M) |
| Income Tax Expense | 6.7M | 7.0M | 3.4M | 1.6M | 13.6M |
| Bottom Line | |||||
| Net Income | 4.1M | 3.5M | 30.5M | (35.1M) | (498.6M) |
| Earnings from Cont. Ops | 9.0M | 8.6M | 35.6M | (31.9M) | (495.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.1M | 3.5M | 30.5M | (35.1M) | (498.6M) |
| Per Share | |||||
| Basic EPS | CN¥0.01 | CN¥0.00 | CN¥0.04 | (CN¥0.05) | (CN¥0.64) |
| Diluted EPS | CN¥0.01 | CN¥0.00 | CN¥0.04 | (CN¥0.05) | (CN¥0.64) |
| Revenue Per Share | CN¥0.39 | CN¥0.40 | CN¥0.42 | CN¥0.42 | CN¥0.48 |
| Shares | |||||
| Basic Shares Outstanding | 788.4M | 776.1M | 775.6M | 701.7M | 779.1M |
| Diluted Shares Outstanding | 788.4M | 776.1M | 775.6M | 701.7M | 779.1M |
| Profitability Metrics | |||||
| EBITDA | — | 43.2M | 70.3M | 5.6M | (450.2M) |
| D&A | — | 29.1M | 29.9M | 31.2M | 29.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026